New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.
about
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analoguesAdolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.
P2860
New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.
@en
type
label
New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.
@en
prefLabel
New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.
@en
P2860
P1476
New strategies in Hodgkin lymphoma: better risk profiling and novel treatments
@en
P2093
Christian Steidl
P2860
P304
P356
10.1158/1078-0432.CCR-12-3064
P407
P577
2013-02-27T00:00:00Z